AAAAAA

   
Results: 1-7 |
Results: 7
OLIGOCLONAL PROTEIN BANDS AND IG ISOTYPE SWITCHING IN MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE THERAPY AND HEMATOPOIETIC-CELL TRANSPLANTATION
Authors: ZENT CS WILSON CS TRICOT G JAGANNATH S SIEGEL D DESIKAN KR MUNSHI N BRACY D BARLOGIE B BUTCH AW
Citation: Cs. Zent et al., OLIGOCLONAL PROTEIN BANDS AND IG ISOTYPE SWITCHING IN MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE THERAPY AND HEMATOPOIETIC-CELL TRANSPLANTATION, Blood, 91(9), 1998, pp. 3518-3523
THE CHIMERIC GENES AML1 MDS1 AND AML1/EAP INHIBIT AML1B ACTIVATION ATTHE CSF1R PROMOTER, BUT ONLY AML1/MDS1 HAS TUMOR-PROMOTER PROPERTIES/
Authors: ZENT CS MATHIEU C CLAXTON DF ZHANG DE TENEN DG ROWLEY JD NUCIFORA G
Citation: Cs. Zent et al., THE CHIMERIC GENES AML1 MDS1 AND AML1/EAP INHIBIT AML1B ACTIVATION ATTHE CSF1R PROMOTER, BUT ONLY AML1/MDS1 HAS TUMOR-PROMOTER PROPERTIES/, Proceedings of the National Academy of Sciences of the United Statesof America, 93(3), 1996, pp. 1044-1048
SERUM OLIGOCLONAL PROTEIN BANDS AND IMMUNNOGLOBULIN ISOTYPE SWITCH INPATIENTS (PTS) RECEIVING AUTOTRANSPLANTS (AT) FOR MULTIPLE-MYELOMA (MM)
Authors: ZENT CS TRICOT G JAGANNATH S SIEGEL D DESIKAN KR MUNSHI N BRACY D BARLOGIE B BUTCH AW
Citation: Cs. Zent et al., SERUM OLIGOCLONAL PROTEIN BANDS AND IMMUNNOGLOBULIN ISOTYPE SWITCH INPATIENTS (PTS) RECEIVING AUTOTRANSPLANTS (AT) FOR MULTIPLE-MYELOMA (MM), Blood, 88(10), 1996, pp. 1563-1563
CYCLIC THROMBOCYTOPENIA - THROMBOPOIETIN RESPONSE TO SPONTANEOUS CHANGES IN PLATELET COUNTS
Authors: ZENT CS HORNKOHL A AREPALLY G RATAJCZAK J ANASTASI J GEWIRTZ AM HOFFMAN PC
Citation: Cs. Zent et al., CYCLIC THROMBOCYTOPENIA - THROMBOPOIETIN RESPONSE TO SPONTANEOUS CHANGES IN PLATELET COUNTS, Blood, 86(10), 1995, pp. 1470-1470
AML1 MDS1 AND AML1/EAP BIND SPECIFICALLY TO AN AML1 DNA-BINDING SITE AND INHIBIT AML1B TRANSACTIVATION OF THE CSFIR PROMOTER DESPITE OVEREXPRESSION OF CBFB/
Authors: ZENT CS MATHIEU C CLAXTON DF ROWLEY JD NUCIFORA G
Citation: Cs. Zent et al., AML1 MDS1 AND AML1/EAP BIND SPECIFICALLY TO AN AML1 DNA-BINDING SITE AND INHIBIT AML1B TRANSACTIVATION OF THE CSFIR PROMOTER DESPITE OVEREXPRESSION OF CBFB/, Blood, 86(10), 1995, pp. 2376-2376
CLONAL EVOLUTION OF INV(16)(P13Q22) IN 2 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST PHASE
Authors: ZENT CS LEBEAU MM DALY KM ONG TS LESTER EP LARSON RA
Citation: Cs. Zent et al., CLONAL EVOLUTION OF INV(16)(P13Q22) IN 2 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST PHASE, Clinical research, 42(3), 1994, pp. 10000376-10000376
PREDICTION OF AMIKACIN DOSE REQUIREMENTS IN NEUTROPENIC PATIENTS WITHHEMATOLOGICAL DISEASE
Authors: ZENT CS ALLIN R FOLB PI
Citation: Cs. Zent et al., PREDICTION OF AMIKACIN DOSE REQUIREMENTS IN NEUTROPENIC PATIENTS WITHHEMATOLOGICAL DISEASE, South African medical journal, 83(11), 1993, pp. 853-854
Risultati: 1-7 |